Bedaquiline pharmacokinetics in drug-resistant tuberculosis: from exposure variability to individualized therapy
4 affiliations
- 1Department of Tuberculosis, Shandong Public Health Clinical Center, Shandong University , ,
- 2Guangxi Key Laboratory of Artificial Intelligence for Genetic Diseases of Long-Dwelling Nationalities , ,
- 3Department of Pediatrics, Affiliated Hospital of Youjiang Medical University for Nationalities , , ,
- 4Department of Lab Medicine, Shandong Public Health Clinical Center, Shandong University , ,
Abstract
Bedaquiline has transformed the treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) and is now a core component of contemporary all-oral regimens. However, translating its distinctive pharmacokinetic properties into individualized clinical management remains challenging. Bedaquiline exhibits food-enhanced absorption, extensive plasma protein binding, broad but heterogeneous tissue distribution, cytochrome P450 3A4-mediated metabolism to the N-monodesmethyl metabolite M2, and prolonged persistence caused by tissue sequestration and slow redistribution. These features contribute to substantial interindividual variability, clinically important drug–drug interactions, delayed accumulation, and residual exposure long after treatment discontinuation. This narrative review synthesizes current evidence on the absorption, distribution, metabolism, and elimination of bedaquiline; population pharmacokinetic models and determinants of exposure variability; target-site penetration; pharmacokinetics in children, pregnancy, organ dysfunction, and HIV coinfection; and clinically relevant interactions with antituberculosis and antiretroviral drugs. We also critically evaluate exposure–efficacy and exposure–toxicity relationships, including evidence from bedaquiline-containing multidrug regimens, and examine the potential roles of therapeutic drug monitoring, minimum inhibitory concentration-normalized exposure indices, and model-informed precision dosing. Current evidence supports administration with food, avoidance of potent CYP3A inducers, caution during prolonged CYP3A inhibition, and intensified electrocardiographic and electrolyte monitoring when QT-prolonging agents are combined. Nevertheless, no plasma, M2, area-under-the-curve, or susceptibility-normalized exposure target has been prospectively validated for routine dose adjustment. Covariate effects identified by population models are inconsistent across cohorts, and pharmacokinetic evidence remains limited in several special populations. Individualized assessment may therefore be appropriate when clinically meaningful uncertainty exists, but empirical departure from standard dosing is not currently justified. Progress toward precision dosing will require standardized sampling and susceptibility testing, measurement of unbound and target-site exposure, externally validated pharmacokinetic–pharmacodynamic models, and prospective demonstration that exposure-guided interventions improve clinical outcomes.
Related
- Challenges of Using a Bedaquiline-Based Regimen to Treat Multidrug-Resistant Tuberculosis in Pregnancy
- Emergence and characterisation of bedaquiline, pretomanid and linezolid resistance in recurrent rifampicin-resistant tuberculosis patient: A case report
- Incidence and Predictors of QTC Prolongation Among Drug-Resistant Tuberculosis Patients Receiving Bedaquiline-Based TB Regimens in Uganda: A Countrywide Retrospective Cohort Study.
- Temporal proximity to counseling is associated with longitudinal bedaquiline and antiretroviral therapy adherence in multidrug-resistant tuberculosis and HIV treatment
- Neuropsychiatric effects of cycloserine with bedaquiline, delamanid, and conventional therapy in drug-resistant tuberculosis: a multicenter retrospective cohort study from China
BibTeX
@article{xiong2026bedaquiline,
title = {{Bedaquiline pharmacokinetics in drug-resistant tuberculosis: from exposure variability to individualized therapy}},
author = {Yu Xiong and Jun-Li Wang and Dong-Yan Wei and Yue-Yan Huang and Mao-Shui Wang},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1941682},
url = {https://europepmc.org/article/PMC/PMC13670025},
note = {CC BY},
}
RIS
TY - JOUR
TI - Bedaquiline pharmacokinetics in drug-resistant tuberculosis: from exposure variability to individualized therapy
AU - Yu Xiong
AU - Jun-Li Wang
AU - Dong-Yan Wei
AU - Yue-Yan Huang
AU - Mao-Shui Wang
PY - 2026
DA - 2026/10/01
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1941682
UR - https://europepmc.org/article/PMC/PMC13670025
AB - Bedaquiline has transformed the treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) and is now a core component of contemporary all-oral regimens. However, translating its distinctive pharmacokinetic properties into individualized clinical management remains challenging. Bedaquiline exhibits food-enhanced absorption, extensive plasma protein binding, broad but heterogeneous tissue distribution, cytochrome P450 3A4-mediated metabolism to the N-monodesmethyl metabolite M2, and prolonged persistence caused by tissue sequestration and slow redistribution. These features contribute to substantial interindividual variability, clinically important drug–drug interactions, delayed accumulation, and residual exposure long after treatment discontinuation. This narrative review synthesizes current evidence on the absorption, distribution, metabolism, and elimination of bedaquiline; population pharmacokinetic models and determinants of exposure variability; target-site penetration; pharmacokinetics in children, pregnancy, organ dysfunction, and HIV coinfection; and clinically relevant interactions with antituberculosis and antiretroviral drugs. We also critically evaluate exposure–efficacy and exposure–toxicity relationships, including evidence from bedaquiline-containing multidrug regimens, and examine the potential roles of therapeutic drug monitoring, minimum inhibitory concentration-normalized exposure indices, and model-informed precision dosing. Current evidence supports administration with food, avoidance of potent CYP3A inducers, caution during prolonged CYP3A inhibition, and intensified electrocardiographic and electrolyte monitoring when QT-prolonging agents are combined. Nevertheless, no plasma, M2, area-under-the-curve, or susceptibility-normalized exposure target has been prospectively validated for routine dose adjustment. Covariate effects identified by population models are inconsistent across cohorts, and pharmacokinetic evidence remains limited in several special populations. Individualized assessment may therefore be appropriate when clinically meaningful uncertainty exists, but empirical departure from standard dosing is not currently justified. Progress toward precision dosing will require standardized sampling and susceptibility testing, measurement of unbound and target-site exposure, externally validated pharmacokinetic–pharmacodynamic models, and prospective demonstration that exposure-guided interventions improve clinical outcomes.
SN - 1663-9812
ER -